Tumor-targeting prodrug-activating bacteria for cancer therapy (Q46680275)

24 December 2017

title

Tumor-targeting prodrug-activating bacteria for cancer therapy (English)

1 reference

24 December 2017

author name string

C-M Cheng

1

1 reference

24 December 2017

Y-L Lu

2

1 reference

24 December 2017

K-H Chuang

3

1 reference

24 December 2017

W-C Hung

4

1 reference

24 December 2017

J Shiea

5

1 reference

24 December 2017

Y-C Su

6

1 reference

24 December 2017

C-H Kao

7

1 reference

24 December 2017

B-M Chen

8

1 reference

24 December 2017

S Roffler

9

1 reference

24 December 2017

T-L Cheng

10

1 reference

24 December 2017

publication date

28 March 2008

1 reference

24 December 2017

published in

Cancer Gene Therapy

1 reference

24 December 2017

volume

15

1 reference

24 December 2017

issue

6

1 reference

24 December 2017

page(s)

393-401

1 reference

24 December 2017

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Bacteriolytic therapy can generate a potent immune response against experimental tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

A bacterial protein enhances the release and efficacy of liposomal cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Downregulation of innate and acquired antitumor immunity by bystander gammadelta and alphabeta T lymphocytes with Th2 or Tr1 cytokine profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

The gusBC genes of Escherichia coli encode a glucuronide transport system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

A2A adenosine receptor protects tumors from antitumor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Galectin-1: a link between tumor hypoxia and tumor immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Prodrug Mono therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Pressure effects on mechanisms of charge transport across bilayer membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Bacterial gene therapy strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Cloning and nucleotide sequences of lux genes and characterization of luciferase of Xenorhabdus luminescens from a human wound

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Intensely cytotoxic anthracycline prodrugs: glucuronides

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Human serum β-glucuronidase; its measurement and some of its properties

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Tumor-targeted Salmonella. Highly selective delivery vectors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2008.10

7 January 2021

Identifiers

DOI

10.1038/CGT.2008.10

1 reference

24 December 2017

1 reference

24 December 2017